Infant Bacterial Therapeutics Overview

  • Founded
  • 2013
  • Status
  • Public
  • Employees
  • 10
  • Stock Symbol
  • IBT B
Stock Symbol
  • Share Price
  • $12.18
  • (As of Friday Closing)

Infant Bacterial Therapeutics General Information


Infant Bacterial Therapeutics AB is a pharmaceutical company that develops drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. It is currently developing its lead drug candidate IBP-9414, to prevent NEC and improving feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Stock Exchange
Primary Office
  • Gamla Brogatan 11
  • 111 20 Stockholm
  • Sweden
+46 08-410 000 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Infant Bacterial Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$12.18 $12.56 $9.05 - $25.89 $137M 11.2M 17.1K -$0.70

Infant Bacterial Therapeutics Financials Summary

In Thousands,
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 101,662 101,662 125,199 113,003
Revenue 0 0 0 0
EBITDA (7,711) (7,711) (4,904) (4,436)
Net Income (7,810) (7,810) (4,897) (4,667)
Total Assets 54,896 54,896 55,432 62,675
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Infant Bacterial Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Infant Bacterial Therapeutics‘s full profile, request access.

Request a free trial

Infant Bacterial Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Staffan Strömberg Ph.D Chief Executive Officer
Anders Kronström Chief Technology Officer
Sanjiv Sharma Chief Commercial Officer
You’re viewing 3 of 4 executive team members. Get the full list »

Infant Bacterial Therapeutics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial